Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. [version 2; peer review: 2 approved]

Nanchahal, J, Ball, C, Swettenham, J et al. (9 more authors) (2017) Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. [version 2; peer review: 2 approved]. Wellcome Open Research, 2. 37. ISSN 2398-502X

Abstract

Metadata

Authors/Creators:
Commentary on: Nanchahal, J, Ball, C, Swettenham, J et al. (9 more authors) (2017) Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. [version 1; peer review: 1 approved, 1 approved with reservations]. Wellcome Open Research, 2. 37. ISSN 2398-502X
Copyright, Publisher and Additional Information: © 2017 Nanchahal J et al. This is an open access article under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/)
Keywords: Dupuytren’s disease; RCT; anti-TNF; fibrosis; adalimumab
Dates:
  • Published (online): 16 November 2017
  • Published: 16 November 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Feb 2020 12:22
Last Modified: 21 Feb 2020 14:45
Status: Published
Publisher: F1000 Research
Identification Number: https://doi.org/10.12688/wellcomeopenres.11466.2

Commentary/Response Threads

Share / Export

Statistics